Latest news

• A new option for people with HIV

  Other integrase inhibitors. Raltegravir ( Isentress; Merck) was the first integrase inhibitor to be approved by the US FDA in October 2007. ... tenofovir disoproxil fumarate (Atripla) and raltegravir (Isentress).

• FDA clears Isentress formulation for infants with HIV

  A new formulation of Merck &Co's drug Isentress has been cleared in the US to treat infants and children with HIV infection. ... By expanding the potential audience of Isentress, Merck will hope it can keep up in an increasingly competitive market for

• ViiV's Tivicay for HIV on course for EU approval

  Tivicay is the third entrant in the integrase inhibitor class after Merck &Co's Isentress (raltegravir) - which was first approved in 2007 - and Gilead Sciences' elvitegravir which was approved last year ... As the first entrant, Isentress is enjoying

• ViiV gets US nod for HIV drug dolutegravir

  a twice-daily treatment with rival integrase inhibitor Isentress (raltegravir) from Merck &Co and found they were equivalent in previously-untreated HIV patients. ... The SAILING study found that Tivicay was more effective than Isentress in suppressing

• Merck profit slides as generics continue to bite

  HIV drug Isentress (raltegravir) climbed 5 per cent to $410m, holding up fairly well despite increased competition from the likes of Gilead Sciences' elvitegravir, while sales of cholesterol drugs Zetia (ezetimibe)